(19)
(11) EP 3 406 242 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
12.07.2023 Bulletin 2023/28

(45) Mention of the grant of the patent:
07.06.2023 Bulletin 2023/23

(21) Application number: 18180517.7

(22) Date of filing: 17.08.2011
(51) International Patent Classification (IPC): 
A61K 31/00(2006.01)
A61P 1/16(2006.01)
 A61K 38/04(2006.01)
A61P 13/12(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 38/04; G01N 33/6893; G01N 2333/705; G01N 2500/00; G01N 2800/085; G01N 2800/28; G01N 2800/347; G01N 2800/52; A61K 38/10; A61P 1/16; A61P 13/12

(54)

TLR4 ANTAGONIST FOR USE IN THE TREATMENT OF INCREASED AMMONIA PLASMA LEVELS

TLR4 ANTAGONIST ZUR BEHANDLUNG VON ERHÖHTEN PLASMA AMMONIAK WERTEN

ANTAGONISTE DU TLR4 DESTINÉ À ÊTRE UTILISÉ DANS LE TRAITEMENT DE L'AUGMENTATION DES TAUX PLASMATIQUES D'AMMONIAC

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 17.08.2010 GB 201013785

(43) Date of publication of application:
28.11.2018 Bulletin 2018/48

(62) Application number of the earlier application in accordance with Art. 76 EPC:
11748969.0 / 2605763

(73) Proprietor: Yaqrit Limited
Ledbury HR8 1RZ (GB)

(72) Inventors:
  • JALAN, Rajiv
    Chislehurst, BR7 5EP (GB)
  • SHAH, Naina
    Croydon, CR0 6QF (GB)

(74) Representative: J A Kemp LLP 
80 Turnmill Street
London EC1M 5QU
London EC1M 5QU (GB)


(56) References cited: : 
   
  • KITAZAWA TOSHIYUKI ET AL: "Therapeutic approach to regulate innate immune response by Toll-like receptor 4 antagonist E5564 in rats with D-galactosamine-induced acute severe liver injury", JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY INTERSCIENCE, MELBOURNE, AU, vol. 24, no. 6, 1 June 2009 (2009-06-01), pages 1089-1094, XP009152110, ISSN: 0815-9319, DOI: 10.1111/J.1440-1746.2008.05770.X [retrieved on 2009-02-15]
  • CUNNINGHAM PATRICK N ET AL: "Role of toll-like receptor 4 in endotoxin-induced acute renal failure.", JOURNAL OF IMMUNOLOGY, vol. 172, no. 4, 15 February 2004 (2004-02-15), pages 2629-2635, XP009152192, ISSN: 0022-1767
  • ZAGER RICHARD A ET AL: "Toll-like receptor (TLR4) shedding and depletion: acute proximal tubular cell responses to hypoxic and toxic injury", AMERICAN JOURNAL OF PHYSIOLOGY: RENAL PHYSIOLOGY, AMERICAN PHYSIOLOGICAL SOCIETY, UNITED STATES, vol. 292, no. 1, 1 January 2007 (2007-01-01), pages F304-F312, XP009152133, ISSN: 1931-857X, DOI: 10.1152/AJPRENAL.00237.2006 [retrieved on 2006-08-01]
  • SEKI EKIHIRO ET AL: "TLR4 mediates inflammation and fibrogenesis after bile duct ligation", HEPATOLOGY, WILLIAMS AND WILKINS, BALTIMORE, MD, US, vol. 42, no. 4, Suppl. 1, 1 October 2005 (2005-10-01), pages 265A-266A, XP009152038, ISSN: 0270-9139 [retrieved on 2005-10-05]
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).